 |
인쇄하기
취소
|
Novartis's Tasigna receives first approval in Switzerland
Novartis's cancer treatment Tasigna has received approval in Switzerland, its first certification worldwide.
Switzerland is the first country to approve the drug, which offers a cancer therapy for patients with a form of the life-threatening blood cancer chronic myeloid leukemia who are resistant or intolerant to treatment with Gliveca.
Additional regulatory decisions on Tasigna are expe...
Switzerland is the first country to approve the drug, which offers a cancer therapy for patients with a form of the life-threatening blood cancer chronic myeloid leukemia who are resistant or intolerant to treatment with Gliveca.
Additional regulatory decisions on Tasigna are expe...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.